Rusfertide Market Summary

Key Factors Driving Rusfertide Growth

1. First-in-class therapy targeting the underlying mechanism of iron regulation:

Rusfertide is a hepcidin mimetic peptide that controls iron availability for erythropoiesis, thereby reducing excessive red blood cell production in PV. Unlike existing cytoreductive therapies, rusfertide directly addresses iron dysregulation and significantly decreases the need for therapeutic phlebotomy, a major burden for PV patients. Its novel mechanism positions it as a potential new standard adjunctive therapy for patients requiring frequent phlebotomies.

2. Strong Phase III VERIFY efficacy supporting broad physician adoption:

The pivotal Phase III VERIFY trial met its primary endpoint, with 77% of rusfertide-treated patients achieving clinical response versus 33% with placebo (p<0.0001) during Weeks 20–32. The study also met all four key secondary endpoints, including a reduction in mean phlebotomies (0.5 vs. 1.8 per patient), significantly improved hematocrit control, and better patient-reported outcomes. These compelling data provide strong evidence for adoption in routine clinical practice following approval.

3. Durable long-term efficacy and favorable safety profile:

Long-term follow-up from the REVIVE/THRIVE extension studies demonstrated sustained efficacy for up to four years, including a 13-fold reduction in the annual rate of therapeutic phlebotomies compared with baseline. In addition, 52-week Phase III data presented at the 2025 ASH Annual Meeting confirmed durable hematocrit control without new safety signals, reinforcing physician confidence in chronic use.

4. Regulatory momentum and near-term commercialization:

Rusfertide has received Orphan Drug and Fast Track designations from the U.S. FDA, and in March 2026 the FDA accepted the New Drug Application (NDA) and granted Priority Review, with a PDUFA target action date in Q3 2026. These regulatory milestones substantially reduce commercialization risk and position Takeda and Protagonist Therapeutics for a potential U.S. launch shortly after approval.

5. Large addressable market with significant unmet need:

Approximately 30–40% of patients with polycythemia vera remain dependent on repeated therapeutic phlebotomies despite standard-of-care treatment, creating a sizeable opportunity for rusfertide as an add-on therapy. If approved, it could become the preferred option for phlebotomy-dependent PV patients by reducing procedure frequency, improving hematocrit control, and enhancing quality of life. Takeda has identified rusfertide as one of the company's key near-term growth products capable of contributing meaningfully to its post-2026 commercial portfolio.

Rusfertide Recent Developments

In March 2026, Takeda announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In addition to Priority Review, rusfertide has received Breakthrough Therapy designation, Orphan Drug designation and Fast Track designation from the US FDA.

“Rusfertide Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Rusfertide for potential indication like Polycythaemia vera and Haemochromatosis in the 7MM. A detailed picture of Rusfertide’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Rusfertide for potential indications. The Rusfertide market report provides insights about Rusfertide’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Rusfertide performance, future market assessments inclusive of the Rusfertide market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Rusfertide sales forecasts, along with factors driving its market.

Rusfertide Drug Summary

Rusfertide (PTG-300) is an investigational, first-in-class synthetic hepcidin mimetic peptide being developed by Protagonist Therapeutics for the treatment of polycythemia vera (PV) and other disorders characterized by iron dysregulation. Administered as a once-weekly subcutaneous injection, rusfertide mimics the biological activity of the endogenous hormone hepcidin, regulating iron homeostasis by reducing intestinal iron absorption and limiting iron release from macrophages, thereby restricting iron availability for excessive erythropoiesis. By controlling red blood cell production, the therapy is designed to maintain hematocrit levels below 45%, reduce or eliminate the need for therapeutic phlebotomy, and improve disease-related symptoms while minimizing iron deficiency associated with repeated phlebotomies. Clinical studies, including the Phase III VERIFY trial, have demonstrated promising efficacy in reducing phlebotomy requirements and maintaining hematocrit control with a generally manageable safety profile, supporting rusfertide's potential as a novel disease-management option for patients with polycythemia vera if approved. The report provides Rusfertide’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Rusfertide Market Report

The report provides insights into:

• A comprehensive product overview including the Rusfertide MoA, description, dosage and administration, research and development activities in potential indication like Polycythaemia vera and Haemochromatosis.
• Elaborated details on Rusfertide regulatory milestones and other development activities have been provided in Rusfertide market report.
• The report also highlights Rusfertide‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Rusfertide market report also covers the patents information, generic entry and impact on cost cut.
• The Rusfertide market report contains current and forecasted Rusfertide sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Rusfertide market report also features the SWOT analysis with analyst views for Rusfertide in potential indications.

Methodology

The Rusfertide market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Rusfertide Analytical Perspective by DelveInsight

• In-depth Rusfertide Market Assessment

This Rusfertide sales market forecast report provides a detailed market assessment of Rusfertide for potential indication like Polycythaemia vera and Haemochromatosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Rusfertide sales data uptil 2034.

• Rusfertide Clinical Assessment

The Rusfertide market report provides the clinical trials information of Rusfertide for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Rusfertide Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Rusfertide Market Potential & Revenue Forecast

• Projected market size for the Rusfertide and its key indications
• Estimated Rusfertide sales potential (Rusfertide peak sales forecasts)
• Rusfertide Pricing strategies and reimbursement landscape

Rusfertide Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Rusfertide Market positioning compared to existing treatments
• Rusfertide Strengths & weaknesses relative to competitors

Rusfertide Regulatory & Commercial Milestones

• Rusfertide Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Rusfertide Clinical Differentiation

• Rusfertide Efficacy & safety advantages over existing drugs
• Rusfertide Unique selling points

Rusfertide Market Report Highlights

• In the coming years, the Rusfertide market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Rusfertide companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Rusfertide’s dominance.
• Other emerging products for Polycythaemia vera and Haemochromatosis are expected to give tough market competition to Rusfertide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Rusfertide in potential indications.
• Analyse Rusfertide cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Rusfertide sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Rusfertide in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Rusfertide? How strong is Rusfertide’s clinical and commercial performance?
• What is Rusfertide’s clinical trial status in each individual indications such as Polycythaemia vera and Haemochromatosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Rusfertide Manufacturers?
• What are the key designations that have been granted to Rusfertide for potential indications? How are they going to impact Rusfertide’s penetration in various geographies?
• What is the current and forecasted Rusfertide market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Rusfertide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Rusfertide for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Rusfertide? What is the duration of therapy and what are the geographical variations in cost per patient?